Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | ALPL | P05186 | 11/20 | 0.62 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12961091 | 0.85 | ALDH1A1 (0.63) | MEN1KMT2AALDH1A1TP53TDP1 | |
| SCHEMBL2741010 | 0.84 | NPC1 (0.66) | MEN1KMT2ASLC40A1MAPTGAA | |
| SCHEMBL1050831 | 0.84 | ALDH1A1 (0.59) | MEN1KMT2AALDH1A1TP53TDP1 | |
| SCHEMBL1055504 | 0.82 | ALDH1A1 (0.54) | ALDH1A1TP53TDP1ALPLGAA | |
| SCHEMBL1053050 | 0.82 | MEN1 (0.60) | MEN1KMT2AALDH1A1TP53TDP1 | |
| SCHEMBL1053088 | 0.82 | ALDH1A1 (0.60) | MEN1KMT2AALDH1A1TP53TDP1 | |
| SCHEMBL13450486 | 0.81 | MEN1 (0.59) | MEN1KMT2AALPLSLC40A1MAPT | |
| SCHEMBL1055634 | 0.81 | MEN1 (0.65) | MEN1KMT2AALPLSLC40A1MAPT | |
| SCHEMBL1721571 | 0.80 | FFAR4 (0.64) | MEN1KMT2AALDH1A1TP53TDP1 | |
| SCHEMBL14567114 | 0.80 | ALPL (0.50) | MEN1KMT2AALDH1A1TP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868026-B2 | Therapeutic compounds | PFIZER INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868026-B2 | Therapeutic compounds | PFIZER INC. (US) | 2011-01-11 | — | — | US | disclosed |
| EP-1937639-B1 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-1937639-B1 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-1937639-A2 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | Pfizer Products Incorporated (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070167497-A1 | Therapeutic Compounds | PFIZER INC | 2007-07-19 | — | — | US | disclosed |
| US-20070167497-A1 | Therapeutic Compounds | PFIZER INC | 2007-07-19 | — | — | US | disclosed |
| US-20070167497-A1 | Therapeutic Compounds | PFIZER INC | 2007-07-19 | — | — | US | disclosed |
| WO-2007034312-A2 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007034312-A2 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167497-A1 | Therapeutic Compounds | SLC10A1, PCSK9, CFTR | MEN1 1198/4885KMT2A 4636/4885ALDH1A1 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.